Aviva Shares Fall 13% to Below £7 Despite Strong 2025 Results
Investors remain divided over Aviva’s future despite clear signs of progress. The insurer has streamlined operations and hit key targets early. Yet market sentiment still reflects past difficulties.
Market valuation versus peers
On several forward-looking metrics, Aviva trades below its competitors. Its price-to-sales ratio stands at 0.5. The peer group average is 2.1.
- Legal & General: 1.3
- Admiral: 1.7
- Swiss Life: 2.6
- Prudential: 3.1
The insurer’s forward price-to-earnings ratio is 12.6. That compares with a peer average of 12.9. Price-to-book is 1.8, versus a group average of about 4.
Valuation model and fair value
A discounted cash flow assessment suggests substantial upside from current prices. Using a 7.2% discount rate, the model indicates roughly 51% undervaluation. That points to a fair value near £12.43 versus a quoted price of £6.09.
Such gaps can narrow if results and market sentiment align. Investors should consider model assumptions before acting.
Strong 2025 performance and shareholder returns
Aviva reported outperformance for the 2025 financial year on 5 March. Operating profit rose 25% year on year to £2.2bn. Management met the above-£2bn target a year ahead of schedule.
Operating earnings per share increased 17% to 56p. The board announced a £350m share buyback to support returns.
Analyst growth forecasts
Analysts expect earnings to expand at about 15% annually to the end of 2028. The projection underpins the valuation upside suggested by the DCF.
Headwinds to monitor
Several risks could derail earnings momentum. A sharp market downturn would hit investment values and capital strength. Persistent high inflation could lift costs and compress margins in insurance and savings operations.
These scenarios would affect both short-term results and long-term value creation.
Market reaction and outlook
Short-term market pricing still appears cautious. Headlines such as “Aviva Shares Fall 13% to Below £7 Despite Strong 2025 Results” illustrate lingering scepticism.
Filmogaz.com notes the analyst who ran the valuation said they would increase a personal £20,000 holding. Other undervalued, high-yield FTSE stocks also attracted their attention.
